Amy Bosley

Amy Bosley

E-Mail:  amy-bosley@ouhsc.edu

Phone:  (405)271-2422

CITY/STATE/COUNTRY OF ORIGIN:

Oklahoma City, OK

EDUCATION:

Bethany Lutheran College
Lindsborg, Kansas
BA, Biology

YEAR OF GRADUATE PROGRAM:

2

MENTOR:

Doris Benbrook, PhD
Professor, Department of Obstetrics & Gynecology
Section of Gynecologic Oncology
Co-Director, Center for Chemoprevention and Drug Development, Stephenson Cancer Center
Adjust Professor, Pathology

PROGRAM DESCRIPTION

Cervical cancer is one of the most common cancers in women. New treatment options that have a higher efficacy and less toxic effects are required. SHetA2 is a promising treatment and preventative of cervical cancer.  Some of the known mechanisms of action includes the degradation of cyclin D1,  a requirement in G1 to S phase in the cell cycle, and interruption in the p53 and mortalin complex. However, the full mechanism of action of SHetA2 is still largely unknown. A couple of pathways shows potential in their involvement in the mechanism of action of SHetA2: adenine nucleotide translocase (ANT), dickkopf (DKK), and the MAPK/ERK cascade. We have also seen synergistic interactions between SHetA2 and Palbociclib, a CDK 4/6 inhibitor manufactured by Pfizer. So we propose that SHetA2 inhibits cancer growth alone and synergistically in combination with CDK 4/6 inhibitors by inducing G1 cell cycle arrest and apoptosis through a mechanism involving alterations in downstream effectors of SHetA2 binding proteins, leading to cyclin D1 degradation, G1 arrest, and apoptosis.